Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Worldwide, #osteoporosis causes approximately 9 million #fractures annually – resulting in an osteoporosis-related #fracture about every 3 seconds . Tune in to the #ECTS2020 congress to learn how we can improve osteoporosis care and create a world free of
— UCB News (@ucb_news) 23.10.2020 -
Great story about how UCB is using digital technology as part of @covid_moonshot to discover an anti-viral for #COVID19. #digitaltransformation https://t.co/2TC9eXYp2u
— UCB News (@ucb_news) 23.10.2020 -
#ECTS2020 starts today! We are excited to be participating in this years’ virtual congress where we will be partnering with bone specialists across the world to discuss developments in #osteoporosis and #fragilityfracture care! Don’t forget to register: h
— UCB News (@ucb_news) 22.10.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
